Published in Women's Health Weekly, September 25th, 2003
Ovarian cancer is rarely cured and more than 50% of patients die within 5 years of being diagnosed with the disease. Earlier studies had suggested that carboplatin plus paclitaxel might be better tolerated than cisplatin plus paclitaxel. To test this hypothesis, Andreas du Bois, MD, PhD, of the Dr. Horst Schmidt Hospital in Wiesbaden, Germany, and colleagues performed a randomized, Phase III clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.